Denervación renal en el tratamiento de la hipertensión arterial.Posicionamiento conjunto de la SEH-LELHA y la ACI-SEC

  1. Oriol Rodríguez-Leor 1
  2. Fernando Jaén Aguila 2
  3. Julián Segura de la Morena 3
  4. Iván Javier Núñez Gil 4
  5. Arturo García Touchard 5
  6. Esther Rubio 6
  7. Maria Isabel Troya 7
  8. Juan Diego Mediavilla García 2
  9. Angel Cequier 8
  10. Raúl Moreno Gómez 9
  11. Nieves Martell Claros 10
  12. Paola Beltrán 11
  13. Eduardo Molina-Laborda 12
  14. J. A. García Donaire 10
  1. 1 Institut del Cor (ICOR), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España
  2. 2 Servicio de Medicina Interna, Unidad de Riesgo Vascular, Hospital Virgen de las Nieves, Granada, España
  3. 3 Servicio de Nefrología, Hospital 12 de Octubre, Madrid, España
  4. 4 Servicio de Cardiología, Hospital Clínico San Carlos, Madrid, España
  5. 5 Servicio de Cardiología, Hospital Puerta de Hierro, Majadahonda, Madrid, España
  6. 6 Servicio de Nefrología, Hospital Puerta de Hierro, Majadahonda, Madrid, España
  7. 7 Servicio de Nefrología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España
  8. 8 Servicio de Cardiología, Hospital Universitari de Bellvitge, Universidad de Barcelona, IDIBELL, L’Hospitalet de Llobregat, Barcelona, España
  9. 9 Servicio de Cardiología, Hospital de La Paz, Madrid, España
  10. 10 Servicio de Medicina Interna, Hospital Clínico San Carlos, Madrid, España
  11. 11 Servicio de Cardiología, Hospital de Viladecans, IDIBELL, Viladecans, Barcelona, España
  12. 12 Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, España
Montrer des affiliations +
Revue:
REC: Interventional Cardiology

ISSN: 2604-7276,  2604-7306

Année de publication: 2022

Volumen: 4

Número: 1

Pages: 39-46

Type: Article

DOI: 10.24875/RECIC.M21000231 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

D'autres publications dans: REC: Interventional Cardiology

Objetivos de desarrollo sostenible

Résumé

Hypertension is the most prevalent cardiovascular risk factor. Despite pharmacological treatment, a high percentage of patients do not achieve an adequate blood pressure control. Renal sympathetic denervation is a minimally invasive intervention for the management of hypertension involving the interruption of the renal artery sympathetic nervous system using a catheter-based approach. The early studies showed promising results, but the controversial results coming from the SYMPLICITY HTN-3 trial sent this technique into oblivion. Over the last 3 years, new clinical trials have appeared including new devices used in different populations, which definitively proves the effectiveness of renal sympathetic denervation. This joint position statement from the Spanish Society of Hypertension-Spanish League for Combating High Blood Pressure (SEH-LELHA), and the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC) reviews the evidence available on the efficacy and safety profile of renal sympathetic denervation for the management of hypertension. Based on the results of clinical trials, recommendations have been established on what patients may be eligible for renal sympathetic denervation and under what circumstances.

Références bibliographiques

  • 1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-concept cohort study. Lancet 2009;373:1275-1281.
  • 2. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial. Lancet. 2010;376:1903-1909.
  • 3. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
  • 4. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346-2355.
  • 5. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal):a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444-1451.
  • 6. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE HTN-SOLO):a multicentre, international, single-blind, randomised, sham controlled trial. Lancet. 2018;391:2335-2345.
  • 7. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476-2486.
  • 8. Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology:ESH/ESC Task Force for the Management of Arterial Hypertension. Eur Heart J. 2018;39:3021-3104.
  • 9. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the Symplicity HTN-3 trial. Eur Heart J. 2015;36:219-227.
  • 10. Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes:3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40:3474–3482.
  • 11. Janke AT, McNaughton CD, Brody AM, Welch RD, Levy PD. Trends in the incidence of hypertensive emergencies in US emergency departments from 2006 to 2013. J Am Heart Assoc. 2016;5:e004511.
  • 12. Vleck M, Bur A, Woisetschläger C, Herkner H, Laggner AN, Hirschl MM. Association between hypertensive urgencies and subsequent cardiovascular events in patients with hypertension. J Hypertens. 2008;26:657-662.
  • 13. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence:analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25:284-290.
  • 14. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis. Lancet. 2016;387:957-967.
  • 15. Gupta P, Patel P, Strauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69:1113-1120.
  • 16. Cordero A, Morillas P, Bertomeu-Gonzalez V, et al. Prevalence of Peripheral Arterial Disease in Patients with Acute Coronary Syndrome Investigators. Clustering of target organ damage increases mortality after acute coronary syndromes in patients with arterial hypertension. J Hum Hypertens. 2011;25:600-607.
  • 17. Lonnebakken MT, Izzo R, Mancusi C, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J Am Heart Assoc. 2017;6:e004152.
  • 18. Kordalis A, Tsiachris D, Pietri P, et al. Regression of organ damage following renal denervation in resistant hypertension:a meta-analysis. J Hypertens. 2018;36:1614-1621.
  • 19. Schmeider RE, Hogerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension:a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108:1331-1342.
  • 20. Schmieder RE, Redon J, Grassi G, et al. ESH Position Paper:Renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-841.
  • 21. Banegas JR, Messerli FH, Waeber B, et al. Discrepancies between office and ambulatory blood pressure:clinical implications. Am J Med. 2009;122:1136-1141.
  • 22. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62:218-225.
  • 23. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension:when, who, and how to screen?Eur Heart J. 2014;35:1245-1254.
  • 24. García-Touchard A, Maranillo E, Mompeo B, Sañudo JR. Microdissection of the Human Renal Nervous System:Implications for Performing Renal Denervation Procedures. Hypertension. 2020;76:1240-1246.
  • 25. Mahfoud F, Tunev S, Ewen S, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66:1766-1775.
  • 26. Id D, Kaltenbach B, Bertog SC, et al. Does the presence of accessory renal arteries affect the efficacy of renal denervation?JACC Cardiovasc Interv. 2013;6:1085-1091.
  • 27. Tzafriri AR, Mahfoud F, Keating JH, et al. Procedural and anatomical determinants of multi-electrode renal denervation efficacy –Insights from preclinical models. Hypertension. 2019;74:546-554.
  • 28. Tzafriri AR, Mahfoud F, Keating JH, et al Innervations patterns may limit response to endovascular renal denervation. J Am Coll Cardiol. 2014;64:1079-1087.
  • 29. Fink G, Phelps JT. Can we predict the blood pressure response to renal denervation?Auton Neurosci. 2017;204:112-118.
La source de données: Dialnet